Germany is spearheading the European drug delivery market, driven by groundbreaking advancements in nanotechnology, according to a new report by ResearchAndMarkets.com. Valued at $253.65 billion in 2025, the market is projected to grow at a compound annual growth rate (CAGR) of 5.08%, reaching $342.98 billion by 2030. Germany’s leadership in nanotechnology, supported by robust R&D investments, positions it as a key driver of this growth, particularly in addressing chronic diseases through targeted drug delivery systems.
Germany’s dominance in the European drug delivery market is largely due to its pioneering work in nanotechnology. According to European Commissions report, the country hosts 233 of the top 800 R&D EU headquartered companies which invested 247.7 billion EUR in R&D representing an annual growth of +8.7%. This investment has fueled advancements in nanomedicine, enabling precise drug delivery systems that improve treatment outcomes for chronic diseases like cancer, diabetes, and cardiovascular conditions.
Germany’s contributions are expected to have a ripple effect across the region, with the report noting that the country’s innovations are setting the standard for other markets, including the U.K., France, and Switzerland.
Nanotechnology allows for targeted drug delivery, ensuring medications are released at specific sites in the body, minimizing side effects and enhancing efficacy. The report highlights that the rising prevalence of chronic diseases is driving demand for such innovative solutions, with Germany at the forefront of developing Controlled Release Drug Delivery Systems (CRDDS) that leverage nanotechnology. These systems are critical for managing conditions requiring precise dosing, such as neurological disorders and chronic respiratory diseases.